Byong Duk Ye
Asan Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Byong Duk Ye as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:54 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06064864 · Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CDAsan Medical Center · recruiting · Crohn's Disease · principal investigator
- Ph4NCT06051253 · TDM-based Infliximab Treatment for Active Perianal Fistulizing Crohn's DiseaseAsan Medical Center · recruiting · Crohn Disease, Infliximab, Perianal Fistula Due to Crohn's Disease · principal investigator
- N/ANCT01984879 · Vaccination Status, Knowledge and Attitude in Korean Patients With IBDAsan Medical Center · completed · Inflammatory Bowel Disease · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:54 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.Gastroenterology · 2021215 citationsRCR 15.9
- 182 citationsRCR 9.5
- The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study.J Clin Gastroenterol · 201285 citationsRCR 3.3
- Optimized hybrid endoscopic submucosal dissection for colorectal tumors: a randomized controlled trial.Gastrointest Endosc · 201673 citationsRCR 3.9
- 62 citationsRCR 2.1
- Omeprazole may be superior to famotidine in the management of iatrogenic ulcer after endoscopic mucosal resection: a prospective randomized controlled trial.Aliment Pharmacol Ther · 200653 citationsRCR 1.8
- Identification of Ten Additional Susceptibility Loci for Ulcerative Colitis Through Immunochip Analysis in Koreans.Inflamm Bowel Dis · 201641 citationsRCR 1.3
- Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study.J Korean Med Sci · 201040 citationsRCR 1.4
- Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease.PLoS One · 201739 citationsRCR 1.6
- Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial.Clin Drug Investig · 202331 citationsRCR 3.5